Analystreport

Adaptimmune Therapeutics plc (NASDAQ: ADAP) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $4.00 price target on the stock.

Adaptimmune Therapeutics plc - American Depositary Shares  (ADAP) 
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am Check Earnings Report